Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Erlotinib Beyond Progression in NSCLC
NCT00702975Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2008
- Primary completion
- Feb 2013
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Radboud University Medical Center. Primary endpoint: Disease Control Rate at 18 weeks. Started Sep 2008; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00702975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00702975.